Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant TACE + lenvatinib + tislelizumab versus surgery alone for resectable large single HCC
ChiCTR2300075056Phase 2Recruiting
- Sponsor
- Fujian Provincial Hospital
- Start
- Aug 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of lenvatinib and tislelizumab in hepatocellular carcinoma (HCC) (2 arms), sponsored by Fujian Provincial Hospital. Primary endpoint: 1-year recurrence-free survival rate. Started Aug 2023; status: recruiting.
02
Drugs
lenvatinibtislelizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2300075056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300075056.